

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 8/14/2004  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Hemophilia A (F8) 2 Inversions with Reflex to Sequencing and Reflex to Deletion/Duplication**

ARUP test code 3004232

F8 COMP Specimen whole Blood

Family History for Hemophilia A (F8) Unknown

Symptoms for Hemophilia A (F8) Unknown

**Hemophilia A (F8) Interpretation**

**Positive**

Inversion Analysis: Positive for inversion, therefore, F8 sequencing and deletion/duplication testing were not performed.

INDICATION FOR TESTING  
Carrier Status

RESULT  
One pathogenic variant was detected in the F8 gene.

PATHOGENIC VARIANT  
Gene: F8 (NM\_000132.3)  
Variant: Intron 22-A inversion; Heterozygous

INTERPRETATION  
One pathogenic inversion was detected in the factor 8 (F8) gene; thus, this individual is a carrier of hemophilia A. Approximately 30 percent of female carriers have factor VIII activity levels of less than 40 percent and are at risk for bleeding symptoms typically consistent with mild hemophilia A. This individual's offspring have a 50 percent chance of inheriting the variant regardless of sex.

RECOMMENDATIONS  
A baseline factor VIII clotting activity assay should be performed to determine if this individual is at increased risk for bleeding. Genetic consultation is indicated, including a discussion of medical screening and management. At-risk family members should be offered testing for the identified variant (Hemophilia A (F8) 2 Inversions, ARUP test code 2001759).

This result has been reviewed and approved by [REDACTED]

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**BACKGROUND INFORMATION:** Hemophilia A (F8) 2 Inversions with Reflex to Sequencing and Reflex to Deletion/Duplication

**CHARACTERISTICS:** Hemophilia A is characterized by deficiency of factor VIII clotting activity. Less than 1 percent factor VIII activity results in severe deficiency associated with spontaneous joint or deep muscle bleeding. Moderate deficiency (1-5 percent activity) and mild deficiency (6-40 percent activity) are associated with prolonged bleeding after tooth extractions, surgery, or injuries, and recurrent or delayed wound healing. Female carriers of hemophilia A may have increased bleeding tendencies.

**EPIDEMIOLOGY:** 1 in 5,000 live male births worldwide

**CAUSE:** Pathogenic F8 germline variants

**INHERITANCE:** X-linked recessive. In the estimated 30 percent of cases that appear to be de novo, the mother is found to be a carrier at least 80 percent of the time.

**PENETRANCE:** 100 percent in males. Approximately 30 percent of female carriers have factor VIII activity levels of less than 40 percent and are at risk for bleeding symptoms typically consistent with mild hemophilia A.

**CLINICAL SENSITIVITY:** 98 percent

**GENE TESTED:** F8 (NM\_000132.4)

**METHODOLOGY:** F8 intron 22-A and intron 1 inversions detected by inverse PCR and electrophoresis. Capture of all coding exons and exon-intron junctions of the F8 gene, followed by massively parallel sequencing. Sanger sequencing performed as necessary to fill in regions of low coverage and confirm reported variants. Multiplex ligation-dependent probe amplification (MLPA) of the F8 gene.

**ANALYTICAL SENSITIVITY/SPECIFICITY:** The analytical sensitivity and specificity for inversion analysis and MLPA is 99 percent. The analytical sensitivity of sequencing is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions from 1-10 base pairs in size. Variants greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced.

**LIMITATIONS:** A negative result does not exclude a diagnosis of or carrier status for hemophilia A. This test only detects variants within the coding regions and intron-exon boundaries of the F8 gene. Variants in regions that are not included in the preferred transcript are not detected. Regulatory region variants and deep intronic variants, other than the type 1 or type 2 intron 22-A and intron 1 inversions, will not be identified. Rare F8 intron 22-A and intron 1 inversions with different breakpoints may not be detected by this assay. Breakpoints for large deletions/duplications will not be determined. Single exon deletion/duplications may not be detected based on the breakpoints of the rearrangement. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions. This assay may not detect low-level mosaic or somatic variants associated with disease. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Noncoding transcripts were not analyzed.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
F8 COMP Specimen	23-283-107491	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Family History for Hemophilia A (F8)	23-283-107491	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Symptoms for Hemophilia A (F8)	23-283-107491	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hemophilia A (F8) Interpretation	23-283-107491	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-283-107491  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 3 of 3 | Printed: 11/2/2023 1:36:57 PM  
4848